NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

NeuroSense Therapeutics reports positive 12-month results from its PARADIGM Phase 2b study of PrimeC in ALS patients, showing significant improvements in complication-free survival and disease progression. The company plans to submit these findings to the FDA and other regulatory agencies to discuss PrimeC's future development. PrimeC demonstrated a 57% to 73% improvement over placebo in various measures, highlighting its potential as an effective ALS treatment.